Gurugram-based CORE Diagnostics has announced a strategic collaboration with UK-based CanCertain Healthcare, a pioneering healthcare company dedicated to enhancing cancer treatment outcomes. This partnership marks a significant milestone in the field of oncology, aimed at revolutionising how cancer patients receive personalised treatment.

Oncologists are tasked with the challenging responsibility of swiftly determining the most effective treatment plans for each patient. CanCertain Healthcare has set out to address this challenge with its groundbreaking CanCertain® test. By providing valuable insights into the sensitivity or resistance of a patient's tumour to specific cancer drugs, this innovative diagnostic tool empowers oncologists to make more informed treatment decisions. This not only saves precious time but also reduces the financial burden of ineffective treatments.

This collaboration between CORE Diagnostics and CanCertain Healthcare is poised to reshape cancer care by bringing cutting-edge diagnostic capabilities to the forefront of oncology. The focus of this partnership is primarily on empowering healthcare providers and oncologists rather than direct patient interactions. Doctors will be equipped with the vital information needed to prescribe the most appropriate and effective treatments, optimizing the patient's journey toward recovery.

By harnessing the power of advanced diagnostics, they aim to give cancer patients a fighting chance and make personalised cancer treatment a reality.